Provided by Tiger Fintech (Singapore) Pte. Ltd.

Johnson & Johnson

162.98
-1.8000-1.09%
Post-market: 163.600.6200+0.38%19:57 EDT
Volume:11.30M
Turnover:1.84B
Market Cap:392.14B
PE:18.14
High:164.70
Open:163.18
Low:162.30
Close:164.78
Loading ...

BRIEF-J&J Says Imbruvica Gets Positive CHMP Nod for Untreated MCL Eligible For Stem Cell Transplant

Reuters
·
20 Jun

Johnson & Johnson's DARZALEX® (daratumumab) Receives Positive CHMP Opinion for High-Risk Smouldering Multiple Myeloma, Pending European Commission Approval

Reuters
·
20 Jun

Darzalex® (Daratumumab) Receives the First Positive Chmp Opinion for Patients With High-Risk Smouldering Multiple Myeloma

THOMSON REUTERS
·
20 Jun

Imbruvica® (Ibrutinib) Receives Positive Chmp Opinion for the Treatment of Patients With Previously Untreated Mantle Cell Lymphoma (Mcl) Who Would Be Eligible for Autologous Stem Cell Transplant

THOMSON REUTERS
·
20 Jun

BRIEF-J&J Launches Volt Wrist And Proximal Humerus Plating Systems In US

Reuters
·
20 Jun

J&J: Launches Volt Wrist and Proximal Humerus Plating Systems in the U.S.

THOMSON REUTERS
·
19 Jun

Johnson & Johnson Ordered to Pay $8 Million in Massachusetts Talc Mesothelioma Case

Reuters
·
19 Jun

AbbVie's migraine drug meets main goal of late-stage study

Reuters
·
18 Jun

2 Dividend Stocks to Buy and Never Sell

Motley Fool
·
18 Jun

Dow's Nearly 150-Point Drop Led By Losses For Nike, Merck Shares

Dow Jones
·
18 Jun

Johnson & Johnson Seeks U.S. FDA Approval of Stelara® (Ustekinumab) for the Treatment of Pediatric Crohn’s Disease

THOMSON REUTERS
·
17 Jun

Trump Says Pharma Tariffs Coming Very Soon

Reuters
·
17 Jun

Johnson & Johnson Launches New Tecnis Odyssey Next-Generation Intraocular Lens in Europe, the Middle East, and Canada Offering Cataract Patients Precise Vision at Every Distance in Any Lighting*†‡1,6

THOMSON REUTERS
·
17 Jun

Johnson & Johnson Says Drug Combo Study Shows 'Deep, Durable' Responses Multiple Myeloma Patients With Extramedullary Disease

MT Newswires Live
·
16 Jun

BRIEF-Johnson & Johnson Says Talvey,Tecvayli Shows Deep,Durable Responses In Heavily Pretreated Multiple Myeloma Patients With Extramedullary Disease

Reuters
·
15 Jun

Johnson & Johnson Unveils Promising Phase 2 Trial Results for TALVEY® and TECVAYLI® Combo in Treating Extramedullary Multiple Myeloma

Reuters
·
15 Jun

Johnson & Johnson - Combination Therapy Achieves 78.9% Orr, 54.4% Complete Response

THOMSON REUTERS
·
15 Jun

Investigational Combination of First-in-Class Bispecifics Talvey® and Tecvayli® Shows Deep and Durable Responses in Heavily Pretreated Multiple Myeloma Patients With Extramedullary Disease

THOMSON REUTERS
·
15 Jun

Johnson & Johnson - Novel Approach Shows Potential in Extramedullary Disease Patients

THOMSON REUTERS
·
15 Jun

Johnson & Johnson - Phase 2 Study Shows 78.9% Overall Response Rate

THOMSON REUTERS
·
15 Jun